A mechanistic tumor penetration model to guide antibody drug conjugate design

PloS One
Christina VasalouBruce Gomes

Abstract

Antibody drug conjugates (ADCs) represent novel anti-cancer modalities engineered to specifically target and kill tumor cells expressing corresponding antigens. Due to their large size and their complex kinetics, these therapeutic agents often face heterogeneous distributions in tumors, leading to large untargeted regions that escape therapy. We present a modeling framework which includes the systemic distribution, vascular permeability, interstitial transport, as well as binding and payload release kinetics of ADC-therapeutic agents in mouse xenografts. We focused, in particular, on receptor dynamics such as endocytic trafficking mechanisms within cancer cells, to simulate their impact on tumor mass shrinkage upon ADC administration. Our model identified undesirable tumor properties that can impair ADC tissue homogeneity, further compromising ADC success, and explored ADC design optimization scenarios to counteract upon such unfavorable intrinsic tumor tissue attributes. We further demonstrated the profound impact of cytotoxic payload release mechanisms and the role of bystander killing effects on tumor shrinkage. This model platform affords a customizable simulation environment which can aid with experimental data interpretat...Continue Reading

References

Apr 1, 1992·The Journal of Cell Biology·S FelderJ Schlessinger
Sep 12, 1995·Proceedings of the National Academy of Sciences of the United States of America·T SagaJ N Weinstein
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·D A BerkR K Jain
Mar 1, 1997·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·J R LessR K Jain
Dec 31, 1997·Mathematical Biosciences·J C Panetta
Jan 1, 1995·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·J NarulaB A Khaw
Apr 15, 1993·Physical Review. B, Condensed Matter·J L Mercer, M Y Chou
Mar 29, 2001·Proceedings of the National Academy of Sciences of the United States of America·A PluenR K Jain
Jun 5, 2003·Nature Biotechnology·Svetlana O DoroninaPeter D Senter
Sep 26, 2003·Biophysical Journal·Bart S HendriksDouglas Lauffenburger
Sep 10, 2005·Nature Biotechnology·Philipp Holliger, Peter J Hudson
Mar 7, 2006·Nature Reviews. Drug Discovery·Gergely SzakácsMichael M Gottesman
Jul 27, 2006·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·M-Y WuR-M Zheng
May 17, 2007·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Greg M ThurberK Dane Wittrup
Oct 24, 2007·Proceedings of the National Academy of Sciences of the United States of America·Konstantin StoletovRichard Klemke
Jan 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John C PanettaClinton F Stewart
Jul 23, 2008·Molecular Cancer Therapeutics·Margaret E AckermanK Dane Wittrup
Oct 15, 2009·Molecular Cancer Therapeutics·Michael M Schmidt, K Dane Wittrup
Jan 21, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicole M OkeleyStephen C Alley
Jul 21, 2010·Current Opinion in Chemical Biology·Stephen C AlleyPeter D Senter
Dec 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard A BurrisJoyce A O'Shaughnessy
Sep 22, 2011·PloS One·Greg Michael Thurber, Ralph Weissleder
Dec 7, 2011·Journal of Pharmacokinetics and Pharmacodynamics·Dhaval K Shah, Alison M Betts
Mar 26, 2013·Natural Product Reports·Hans-Peter GerberRobert T Abraham
May 3, 2013·Cold Spring Harbor Perspectives in Biology·Lai Kuan Goh, Alexander Sorkin

❮ Previous
Next ❯

Citations

Nov 26, 2015·Nature Reviews. Clinical Oncology·Dominique BarbolosiNicolas André
Apr 6, 2016·Expert Opinion on Biological Therapy·Serengulam V GovindanDavid M Goldenberg
Apr 5, 2017·CPT: Pharmacometrics & Systems Pharmacology·A M Stein, R Ramakrishna
Nov 11, 2017·Nature Reviews. Cancer·Mark W Dewhirst, Timothy W Secomb
Feb 27, 2018·Chemical Society Reviews·Christopher D SpicerMolly M Stevens
Sep 19, 2017·Journal of Clinical Pharmacology·Heather E VezinaManish Gupta
Sep 20, 2017·Pharmaceutical Research·Paul MalikJonathan Blay
Nov 15, 2018·Chembiochem : a European Journal of Chemical Biology·Vincent HuynhRyan G Wylie
Oct 9, 2018·Antibody Therapeutics·Ying Fu, Mitchell Ho
Jan 18, 2018·Journal of Labelled Compounds & Radiopharmaceuticals·Brooke N McKnight, Nerissa T Viola-Villegas
Aug 23, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Eshita Khera, Greg M Thurber
Apr 1, 2020·American Society of Clinical Oncology Educational Book·Anthony W Tolcher
Mar 31, 2018·Antibodies·Mahendra P DeonarainAshleigh C Stewart
Feb 20, 2021·Expert Opinion on Biological Therapy·Martin De CeccoLisa L McDermott
Oct 27, 2017·Journal of Theoretical Biology·Dan E GanzNeil S Forbes
Sep 13, 2017·Chemical Reviews·Madduri Srinivasarao, Philip S Low
Oct 18, 2019·ACS Medicinal Chemistry Letters·Wei LiWayne C Widdison

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft

Software Mentioned

Matlab

Related Concepts

Related Feeds

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.